Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
35 Cards in this Set
- Front
- Back
Constant proportion of cell population killed rather than a constant number
|
Log-kill hypothesis
|
|
Treatment with cancer chemotherapy at high doses every 3-4 weeks, too toxic to be used continuously
|
Pulse therapy
|
|
Toxic effect of anticancer drug can be lessened by rescue agents
|
Rescue therapy
|
|
Drug used concurrently with toxic anticancer agents to reduce renal precipitation of urates
|
Allopurinol
|
|
Pyrimidine analog that causes "Thymine-less death" given with leucovorin rescue
|
5-flouracil (5-FU)
|
|
Drug used in cancer therapy causes Cushing-like symptoms
|
Prednisone
|
|
Side effect of Mitomycin
|
SEVERE myelosuppression
|
|
MOA of cisplatin
|
Alkylating agent
|
|
Common toxicities of cisplatin
|
Nephro and ototoxicity
|
|
Analog of hypoxanthine, needs HGPRTase for activation
|
6-mercaptopurine (6-MP)
|
|
Interaction with this drug requires dose reduction of 6-MP
|
Allopurinol
|
|
May protect against doxorubicin toxicity by scavenging free radicals
|
Dexrazoxane
|
|
Blows DNA (breaks DNA strands), limiting SE is pulmonary fibrosis
|
Bleomycin
|
|
Bleomycin+vinblastine+etoposide+cisplatin produce almost a 100% response when all agents are used for this neoplasm
|
Testicular cancer
|
|
ABVD regimen used for HD, but appears less likely to cause sterility and secondary malignancies than MOPP
|
Adriamycin (doxorubicin) +bleomycin, vinblastine +dacarbazine
|
|
Regimen used for non-Hodgkin's lymphoma
|
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab
|
|
Regimen used for breast cancer
|
CMF (cyclophosphamide, methotrexate, and fluorouracil) and tamoxifen if ER+
|
|
Alkylating agent, vesicant that causes tissue damage with extravasation
|
Mechlorethamine
|
|
Anticancer drug also used in RA, produces acrolein in urine that leads to hemorrhagic cystitis
|
Cyclophosphamide
|
|
Prevention of cyclophosphamide induced hemorrhagic cystitis
|
Hydration and mercaptoethanesulfonate (MESNA)
|
|
Microtubule inhibitor that causes peripheral neuropathy, foot drop (eg. ataxia), and "pins and needles" sensation
|
Vincristine
|
|
Interact with microtubules (but unlike vinca which prevent disassembly of tubules), it stabilizes tubulin and cells remain frozen in metaphase
|
Paclitaxel (taxol)
|
|
Toxicities include nephrotoxicity and ototoxicity, leading to a severe interaction with aminoglycosides
|
Cisplatin
|
|
Agent similar to cisplatin, less nephrotoxic, but greater myelosuppression
|
Carboplatin
|
|
Converts asparagine to aspartate and ammonia, denies cancer cells of essential AA (asparagine)
|
L-asparaginase
|
|
Used for hairy cell leukemia; it stimulates NK cells
|
Interferon alpha
|
|
Anti-androgen used for prostate cancer
|
Flutamide (Eulexin)
|
|
Anti-estrogen used for estrogen receptor + breast cancer
|
Tamoxifen
|
|
Aromatase inhibitor used in breast cancer
|
Letrozole, anastrozole
|
|
Newer estrogen receptor antagonist used in advanced breast cancer
|
Toremifene (Fareston)
|
|
Some cell cycle specific anti-cancer drugs
|
Bleomycin, vinca alkaloids, antimetabolites (eg., 5-FU, 6-MP, methotrexate, etoposide)
|
|
Some cell cycle non-specific drugs
|
Alkylating agents (eg., mechlorethamine, cyclophosphamide), antibiotics (doxorubicin, daunorubicin), cisplatin, nitrosourea
|
|
Anti-emetics used in association with anti-cancer drugs that are 5-HT3 (serotonin receptor subtype ) antagonists
|
Odansetron, granisetron
|
|
Nitrosoureas with high lipophilicity, used for brain tumors
|
Carmustine (BCNU) and lomustine (CCNU)
|
|
Produces disulfiram-like reaction with ethanol
|
Procarbazine
|